Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir was written by Brandariz-Nunez, David;Correas-Sanahuja, Marcelo;Guarc, Eva;Picon, Rafael;Garcia, Barbara;Gil, Rocio. And the article was included in Medicina Clinica in 2020.Recommanded Product: 242478-37-1 This article mentions the following:
Our objective was to determine thee prevalence of potential interactions in COVID-19 patients receiving lopi-navir/ritonavir(LPV/r). The secondary objective was to develop recommendations and identify the risk factors associated with presenting potential interactions with LPV/r.Cross-sectional and multicenter study with the participation of 2 hospitals. A cross-sectional and multicenter study with the participation of 2 hospitals was performed. COVID-19 patients over 18 years of age, admitted to hospital and under treatment with LPV/r were included. A screening of potential interactions related to LPV/r and home and hospital medication was carried out. Lexicomp (Uptodate), HIV-drug interactions and COVID-drug interactions were used as the query database. The study included 361 patients with a mean age of 62.77 ± 14.64 years where 59.6% (n = 215) were men. 62.3% (n = 225) had 1 or more potential interactions and 26, 87% (n = 97) 2 or more. The independent variables associated with presenting ≥1 potential interactions were age (> 65) (OR 1.95; 95% CI 1.06-3.59, P =.033), ICU admission (OR 9.22; CI 95% 1.98-42.93; P =.005), previous respiratory pathol. (OR 2.90; 95% CI 1.15-7.36; P =.024), psychiatric (OR 4.14; 95 CI % 1.36-12.61; P =.013), dyslipidemia (OR 3.21; 95% CI 1.63-6.35; P =.001) and the number of drugs prescribed (OR 4.33; 95% CI 2.40-7.81; P =.000). The prevalence of potential interactions in COVID-19 patients undergoing treatment with LPV/r is high, with age (> 65), ICU admission, previous respiratory and psychiatric pathol., dyslipidemia and the number of prescribed drugs acting as risk factors. In the experiment, the researchers used many compounds, for example, (S)-(R)-Quinuclidin-3-yl 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (cas: 242478-37-1Recommanded Product: 242478-37-1).
(S)-(R)-Quinuclidin-3-yl 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (cas: 242478-37-1) belongs to isoquinoline derivatives. Quinoline is a catabolite of tryptophan, the basic structure of some antihypertensive drugs, such as the peripheral vasodilators prazosin and doxazosin. The discovery of chloroquine, the most well-known drug containing this stent, has helped bring about decades of malaria control and treatment.Recommanded Product: 242478-37-1
Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem